Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.

Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.

Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.

Histone deacetylase inhibitors (HDACis) are epigenetic agents that display antitumor activities in experimental medulloblastoma (MB). Fingolimod (FTY720), an immunosuppressant agent currently used in the treatment of multiple sclerosis, also has anticancer actions and can act as an HDACi. Here we examined whether fingolimod can inhibit human MB cell viability and survival, and if the effects are accompanied by increased histone acetylation. D283 and DAOY MB cells were treated with different doses of fingolimod. Cell viability was assessed by cell counting in a hemocytometer, and cell survival was analyzed with a colony formation assay. Histone H3 acetylation was measured with an enzyme-linked immunosorbent assay (ELISA). Fingolimod at 7.5 or 10 µM, but not at 5 µM, induced a significant reduction in cell viability in D283 and DAOY cultures, and similar results were observed for inhibition of cell survival. In both cell lines, fingolimod also led to a significant increase in the levels of acetylated H3. These findings provide preliminary evidence indicating that fingolimod induces antitumor activities in MB, possibly through a mechanism which increases H3 histone acetylation.

Popular medicinal uses of Calea uniflora Less. (Asteraceae) and its contribution to the study of Brazilian medicinal plants.

Calea uniflora Less. is widely used in southern Santa Catarina (Brazil), but there are no scientific studies which support its use. Then, this study was proposed to determine of the percentage use of C. uniflora in a city of southern Brazil and documentation of the knowledge that the population has about this species. The survey was conducted with semi-structured interviews using a questionnaire applied to 372 participants. In analyzing the results, it was observed that of the 94.1% who recognized C. uniflora, 74.3% utilize it as a medicinal plant and 65.4% of such knowledge originates in childhood, mainly through the family (84.6%). 93% reported using inflorescences macerated in alcohol or rum; this extract is generally used topically for wound healing and muscle pain. Furthermore, some reported using small quantities of this extract orally to treat cold and flu. Regarding effectiveness and safety, 97% stated an improvement in symptoms with the use of the plant, while 98.5% stated that it has no toxicity. In light of these results, future phytochemical, pharmacological and toxicological analyses should be designed in order to ensure rational and safe use of this species.